Aurora M. Fontainhas

Array ( [id] => 16793000 [patent_doc_number] => 20210122817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => ANTI-MS4A6A ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/965675 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45517 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17938433 [patent_doc_number] => 11472874 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Anti-MS4A4A antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/965676 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 32 [patent_no_of_words] => 68530 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467679 [patent_doc_number] => 11274147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => Binding molecules that specifically bind to tau [patent_app_type] => utility [patent_app_number] => 16/965565 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11152 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 553 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16871524 [patent_doc_number] => 20210164991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => INDUCED COMMON ANTIBODY RESPONSE [patent_app_type] => utility [patent_app_number] => 16/954187 [patent_app_country] => US [patent_app_date] => 2019-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309653 [patent_doc_number] => 20190144530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => TREATMENT OF ALZHEIMER'S DISEASE SUBPOPULATIONS WITH POOLED IMMUNOGLOBULIN G [patent_app_type] => utility [patent_app_number] => 16/247141 [patent_app_country] => US [patent_app_date] => 2019-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16247141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566955 [patent_doc_number] => 20190211084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/239685 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17859811 [patent_doc_number] => 11440957 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Anti-TMEM106B antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/959081 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 55405 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 638 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17756254 [patent_doc_number] => 11396538 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Antibodies to centrin-1, methods of making, and uses thereof [patent_app_type] => utility [patent_app_number] => 16/955751 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 18 [patent_no_of_words] => 25505 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 781 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711928 [patent_doc_number] => 20210079075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => NOVEL MEANS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 16/956255 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16400136 [patent_doc_number] => 20200340994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Tumstatin Assay [patent_app_type] => utility [patent_app_number] => 16/956369 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5938 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338873 [patent_doc_number] => 20190151409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => TREATMENT OF AMD USING AAV2 VARIANT WITH AFLIBERCEPT [patent_app_type] => utility [patent_app_number] => 16/218353 [patent_app_country] => US [patent_app_date] => 2018-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16218353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16861637 [patent_doc_number] => 11020359 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-01 [patent_title] => Method, compositions and device for nano-enhanced opto-chemical trans-differentiation of cells and tissues [patent_app_type] => utility [patent_app_number] => 16/215578 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 9248 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16215578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18215207 [patent_doc_number] => 11590120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Psilocybin compositions [patent_app_type] => utility [patent_app_number] => 16/211281 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5427 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16211281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18345171 [patent_doc_number] => 20230133281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => MATERIALS AND METHODS INCLUDING FOR SEX SELECTION [patent_app_type] => utility [patent_app_number] => 16/768577 [patent_app_country] => US [patent_app_date] => 2018-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915881 [patent_doc_number] => 20210188973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => Activity Modulator [patent_app_type] => utility [patent_app_number] => 16/767979 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17770459 [patent_doc_number] => 11402394 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Antibodies to TTR and methods of use [patent_app_type] => utility [patent_app_number] => 16/198965 [patent_app_country] => US [patent_app_date] => 2018-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 12 [patent_no_of_words] => 14101 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172704 [patent_doc_number] => 11572401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Genetically encoded calcium indicators and methods of use [patent_app_type] => utility [patent_app_number] => 16/198166 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5798 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452596 [patent_doc_number] => 20200362022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF HUMANIZED CONFORMATION-SPECIFIC PHOSPHORYLATED TAU ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/762141 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16762141 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437115 [patent_doc_number] => 20200354441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => TREATMENT OF DISORDERS [patent_app_type] => utility [patent_app_number] => 16/760390 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14836243 [patent_doc_number] => 20190276522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => ANTIBODIES TO ALPHA-SYNUCLEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/170468 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170468 [rel_patent_id] =>[rel_patent_doc_number] =>)